Two Research Initiatives Aimed at Fighting COVID-19

Novochizol SA, a Swiss biotech company with a unique chitosan-based drug formulation nanotechnology, today announced the launch of two research initiatives focusing on COVID-19 prevention and therapeutics in collaboration with researchers at the Center for Antibody Therapeutics (CAT), Division of Infectious Diseases at the University of Pittsburgh.
Read more